COVID-19 Vaccine Governance Pharmaceutical Industry 
Bill of Health
AUGUST 29, 2022
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” By Jorge L.
Bill of Health
DECEMBER 12, 2023
By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines. Impact of the judgment: what have records disclosed shown?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
OCTOBER 26, 2023
Global solidarity requires cooperation between governments, while national solidarity involves cooperation within a state to address common challenges and achieve shared goals. Solidarity operates at two intersecting levels. That has created deep inequities in access to health products that can save lives.
Bill of Health
SEPTEMBER 28, 2023
Such a provision could prevent the public from paying twice for publicly-funded medical products—first through their taxes subsidizing government funded research and development, and second to procure the product in an inflated U.S. pharmaceutical market. Moreover, the NASDAQ Biotechnology Index increased by 374% from 1995 to 2000.
Health Populi
FEBRUARY 22, 2021
The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. The study was written up by Beth Snyder Bulik in FiercePharma.
Expert insights. Personalized for you.
362 
Let's personalize your content